{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PCR-MIB","nct_id":"NCT02662062","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pcr-mib-nct02662062. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PCR-MIB","arms":[{"description":"Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.","label":"Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":["Peter MacCallum Cancer Centre, Australia"],"completion_date":{"date":"2024-08-26","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2025-01-27","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","official_title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-05-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below","timeFrame":"12 weeks of study treatment"}],"references":[{"citation":"Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, Grimison P, Zhang A, Ng S, Tang C, Hovey E, Chen C, Hruby G, Guminski A, McJannett M, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). Eur Urol Oncol. 2024 Jun;7(3):469-477. doi: 10.1016/j.euo.2023.09.011. Epub 2023 Oct 7.","pmid":"37806844","type":"RESULT"}],"start_date":{"date":"2017-07-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT02662062"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pcr-mib-nct02662062"}